Nava Therapeutics emerges with $89M for lipid nanoparticles

Federico Mingozzi, Nava Therapeutics CEO July 15, 2026 09:00 AM EDT FinancingStartupsCell/Gene Tx Ex­clu­sive: Lipid nanopar­ti­cle start­up Na­va emerges with $89M to tar­get T cells and kid­ney Ryan Cross Senior Science Correspondent Na­va Ther­a­peu­tics, a se­cre­tive start­up that’s been work­ing on a new gen­er­a­tion of lipid nanopar­ti­cles that tar­get the bone mar­row, im­mune cells and the kid­ney … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER